ICPE 2024
August 24–28, 2024 | Berlin, Germany
Gold Sponsor
August 2024
Carelon Research is a proud sponsor of ICPE 2024. Visit us in person at booth #802, connect with our experts, and see our latest research. All presentations are in Central European Summer Time (CEST).
SKILLS COURSE
Saturday, August 24, 2024 | 2:30 – 6:00 PM CEST
Session: Pre-conference skills course
Location: Auditorium
Using pharmacoepidemiology database resources to address drug safety research
This course will define the different types of data resources available for pharmacoepidemiology and the selection criteria to select the most appropriate resource.
Daniel Beachler, PhD, MHS
Sr. Director, Safety and Epidemiology
Carelon Research presentations
Carelon Research authors are indicated in bold.
*Associate at time of study.
|
Presentation |
Session |
Title |
Authors |
Affiliations |
|---|---|---|---|---|
|
Oral Monday, August 26 |
Vaccine safety across ages and platforms |
Evaluation of febrile seizure risk following ancestral monovalent COVID-19 mRNA vaccination among U.S. children aged 2-5 years |
Forshee RA[1], Smith ER[2], Wan Z[2], Amend KL[3], Secora A[4], Djibo DA[5], Kazemi K[2], Song J[6], Parlett LE[7], DeShazo J[5], Seeger JD[3], Selvam N[4], McMahill-Walraven CN[5], Hu MI[2], Chillarige Y[2], Anderson SA[1] |
[1]US Food and Drug Administration, Silver Spring, MD, USA, [2]Acumen LLC, Burlingame, CA, USA, [3]Optum Epidemiology, Boston, MA, USA, [4]IQVIA, Falls Church, VA, USA, [5]CVS Health, Blue Bell, PA, USA, [6]United Health, Boston, MA, USA, [7]Carelon Research, Wilmington, DE, USA |
|
Oral Monday, August 26 |
The treatment and prevention of pregnancy-related infections |
Maternal and infant outcomes following exposure to SPIKEVAX during pregnancy: An observational database study |
Kalloo G[1], Guzman M[1], Crowe C[1], Lanes S[1], Coley B[1], Martin D[2], Zhu L[2], Dharia P[2], Esposito D[2] |
[1]Carelon Research, Wilmington, DE, USA, [2]Moderna, Inc., Cambridge, MA, USA |
|
Oral Wednesday, August 28 |
Real ID: methods and validation in pregnancy |
High throughput signal identification of drug use in pregnancy for detection of adverse infant outcomes |
Maro JC[1], Wiley M[1], Cole DV[1], Dashevsky I[1], Ewig CL[2], Haffenreffer K[1], Morris EJ[2], Siranosian E[3], Smolinski NE[2], Thai TN[1], Wang Y[2], Wang Y[2], Wolfe A[1], Suarez EA[4], Parlett LE[5], McMahill-Walraven CH[6], Adgent M[7], Rasmussen SA[8], Winterstein AG[2] |
[1]Dept of Pop Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA, [2]University of Florida, College of Pharmacy, Gainesville, FL, USA, [3]University of North Carolina, Chapel Hill, NC, USA, [4]Rutgers Institute for Health, Boston, MA, USA, [5]Carelon Research, Wilmington, DE, USA, [6]CVS Health, Blue Bell, PA, USA, [7]Dept of Health Policy, Vanderbilt University Medical Center, Nashville, TN, USA, [8]Dept of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA |
|
Poster Monday, August 26 |
Poster session A: CV conditions and treatments |
[152] Characterizing patients with Postural Orthostatic Tachycardia Syndrome (POTS) in claims data after the introduction of a specific diagnosis code |
Hoffman SR[1], Parlett LE[1], Lanes S[1] |
[1]Carelon Research, Wilmington, DE, USA |
|
Poster Monday, August 26 |
Spotlight poster session A: databases |
[ASPOT08] Towards a framework to describe diversity of real-world data sources: Findings from the DIVERSE Initiative |
Pajouheshnia R[1], Gini R[1], Gardarsdottir H[3], Bennett D[4], Li L[5], Gulea C[6], Wientzek-Fleischmann AW[7], Bazelier M[3], Burcu M[8], Dodd CN[9], Duran CE[3], Kaplan S[10], Lanes S[11], Marinier K[12], Roberto G[2], Soman KV[3], Platt RW[13], Iwata SS[14], Hall GC[14], Zhou X[15] |
[1]RTI Health Solutions, Netherlands, [2]ARS Toscana, Florence, Italy, [3]Utrecht University, Utrecht, Netherlands, [4]Takeda, Boston, MA, USA, [5]Sanofi, Bridgewater, NJ, USA, [6]MSD, Zurich, Switzerland, [7]Daiichi Sankyo Europe GmbH, Munich, Germany, [8]Merck & Co., Inc. Rahway, NJ, USA, [9]Panalgo, Amsterdam, Netherlands, [10]Teva Pharmaceutical Industries Ltd, Israel, [11]Carelon Research, Wilmington, DE, USA, [12]IQVIA, Courbevoie, France, [13]McGill University, Montreal, Canada, [14]Rutgers University, Princeton, NJ, USA, [15]Gillian Hall, United Kingdom, [16]Pfizer, Inc., New York, NY, USA |
|
Poster Tuesday, August 27 |
Poster session B: vaccines |
[358] Safety monitoring of bivalent COVID-19 mRNA vaccines among recipients 6 months and older in the United States |
Lloyd PC[1], Smith ER[2], Gruber JF[1], Ondari M[2], Wong HL[1], Hu MI[2], Clarke TC[1], McEvoy R[2], Amend KL[3], Beachler DC[4], McMahill-Walraven CN[5], Seeger JD[3], Secora A[6], Djibo DA[5], Song J[6], Selvam N[7], DeShazo JP[5], Clifford R[3], Abente E[5], Chillarige Y[2], Forshee RA[1], Anderson SA[1], Shoaibi A[1] |
[1]US Food and Drug Administration, Silver Spring, MD, [2]Acumen LLC, Burlingame, CA, USA, [3]Optum Epidemiology, Boston, MA, USA, [4]Carelon Research, Wilmington, DE, USA, [5]CVS Health, Blue Bell, PA, USA, [6]United Health, Boston, MA, USA, [7]IQVIA, Falls Church, VA, USA |
|
Poster Tuesday, August 27 |
Poster session B: pregnancy and lactation |
[275] Linkage of mother and infant records using commercial claims data within the Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative |
Zelaya CE[1], Gruber JF[1], Wan Z[2], Chillarige Y[2], Cho S[1], Hu M[2], Lloyd PC[1], Avula R[3], Lyu R[2], Bell EJ[4], Djibo DA[5], Clark TC[1], Varvaro V[2], Shah N[2], Shah P[2], Amend KL[4], Secora A[6], Selvam N[6], McMahill-Walraven CN[5], Seeger JD[4], Deng J[4], Forshee RA[1], Anderson SA[1], Shoaibi A[1] |
[1]US Food and Drug Administration, Silver Spring, MD, USA, [2]Acumen LLC, Burlingame, CA, USA, [3]Carelon Research, Wilmington, DE, USA, [4]Optum Epidemiology, Boston, MA, USA, [5]CVS Health, Blue Bell, PA, USA, [6]IQVIA, Falls Church, VA, USA |
|
Poster Tuesday, August 27 |
Spotlight poster session B: RWE collaborative |
[BSPOT41] Current applications of machine learning for causal inference in healthcare research using observational data |
Onasanya O[1], Hoffman S[1], Harris K[1], Dixon R[1], Beachler D[1], Grabner, M[1] |
[1]Carelon Research, Wilmington, DE, USA |
|
Poster Tuesday, August 27 |
Poster session B: pregnancy and lactation |
[322] US claims adaptation of the European Concerted Action on Congenital Anomalies and Twins (EUROCAT) Guide 1.5 for use in pregnancy studies |
Hoffman SR[1], Kalloo G[1], Lanes S[1], *Jamal-Allial Aziza[1], Sponhlotz T[1], *Brooks C[1], Guzman M[1], Van Rompay M[1], Onasanya O[1], Willey V[1], Foster E[2], Layton J[2], Ponist D[2], LeNona-Laine M[2], Schroeder K[2] |
[1]Carelon Research, Wilmington, DE, USA, [2]Eili Lilly and Company, Indianapolis, IN |
|
Poster Tuesday, August 27 |
Poster session B: pregnancy and lactation |
[232] Addressing over-representation of early pregnancy outcomes in database pregnancy safety studies |
Van Rompay M[1], *Brooks C[1], Haley V[1], Papazian A[1], Lamberti M[1], *Jamal-Allial A[1], Lanes S[1] |
[1]Carelon Research, Wilmington, DE, USA |
|
Poster Tuesday, August 27 |
Poster session B: pregnancy and lactation |
[316] The IMEDS distributed database network and pregnancy studies |
Clary A[1], Rodriguez-Watson C[2], Huang HS[2], Peeples G[2], Andrade S[3], Connolly JG[3], DeFor TA[3], Deshazo J[4], DiNunzio N[3], Greenlee R[5], *Jamal-Allial A[6], Madow A[7], Mendelsohn AB[3], Pawloski PA[8], Selvan M[9], Singh S[7], Sylwestrzak G[9], Wentz A[6], Zhou Y[9], Toh D[3] |
[1]Evidence to Practice, LLC, USA, [2]Reagan-Udall Foundation for the FDA, [3]Harvard Pilgrim Health Care Institute, Boston, MA, USA, [4]CVS Health, USA, [5]Marshfield Clinic Research Institute, USA, [6]Carelon Research, Wilmington, DE, USA, [7]University of Massachusetts Medical School, USA, [8]HealthPartners Institute, St. Paul, MN, USA, [9]Humana Healthcare Research, USA |
|
Poster Wednesday, August 28 |
Poster session C: vaccines |
[352] Safety of ancestral monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 vaccines in US children aged 6 months to 17 years |
Hu MI[1], Shoaibi A[2], Feng Y[1], Lloyd PC[2], Wong HL[2], Smith ER[1], Amed KL[3], Kline A[4], Beachler DC[5], Gruber JF[2], Mitra M[1], Seeger JD[3], Secora A[6], Obidi J[2], Wang J[1], Song J[7], McMahill-Walraven CN[4], Reich C[6], McEvoy R[1], Do R[1], Chillarige Y[1], Clifford R[3], Forshee R[2], Anderson SA[2] |
[1]Acumen, LLC, Burlingame, CA, USA, [2]US Food and Drug Administration, Silver Spring, MD, USA, [3]Optum Epidemiology, Boston, MA, USA, [4]CVS Health Clinical Trial Services, Blue Bell, PA, USA, [5]Carelon Research, Wilmington, DE, USA, [6]IQVIA, Falls Church, VA, USA, [7]United Health Group, Boston, MA, USA |
|
Poster Wednesday, August 28 |
Poster session C: methods |
[170] Quantifying bias in claims safety studies arising from medication samples: A simple simulation |
Hoffman SR[1], Lanes S[1] |
[1]Carelon Research, Wilmington, DE, USA |
|
Poster Wednesday, August 28 |
Poster session C: vaccines |
[347] Interim utilization results from a post-approval safety study of Pfizer-BioNTech Monovalent COVID-19 vaccine in the United States |
Mayer SE[1], Kawai AT[2], Fuller CC[1], Agan AA[1], Rao S[2], Koram N[3], Calingaert B[2], Marshall J[1], Connolly JG[1], Moyneur E[4], *Jamal-Allial A[5], Brown J[6], Burk J[1], Chomistek A[7], Daniels K[5], Dea K[4], Defor T[8], Diessner B[7], Djibo DA[9], Ezzy SM[7], Hawrusik R[1], Johannes CB[2], Kendrick K[3], Layton JB[2], Ma Q[10], Mai X[1], Mack M[5], Pawloski PA[8], Reynolds JS[1], Selvan M[10], Sharma V[9], Vetter J[9], McMahill-Walraven CN[9], Platt R[1], Gilsenan A[2] |
[1]Harvard Pilgrim Health Care Institute, Boston, MA, USA, [2]RTI, Waltham, MA, USA, [3]Pfizer Inc., New York, NY, USA, [4]Statlog Econometrics L’-Ange-Gardien, Canada, [5]Carelon Research, Wilmington, DE, USA, [6]TriNetX, Cambridge, MA, USA, [7]Optum, Boston, MA, USA, [8]HealthPartners Institute, Bloomington, MI, USA, [9]CVS Health, Elkins Park, PA, USA, [10]Humana Healthcare Research, Inc., Louisville, KY, USA |
|
Poster Wednesday, August 28 |
Poster session C: methods |
[168] Outcome validation to assess misclassification bias in studies using electronic healthcare claims |
*Doherty B[1], Crowe C[1], Sponholtz T[1], Beachler D[1], Lanes S[1] |
[1]Carelon Research, Wilmington, DE, USA |
|
Poster Wednesday, August 28 |
Poster session C: gastrointestinal conditions and treatments |
[050] Compared to thiopurines and tumor necrosis factor inhibitors novel biologics are associated with reduced risk of Non-Melanoma Skin Cancer among patients with Inflammatory Bowel Disease |
Parlett L[1], Ball P[1], Pipkin CA[2], Kappelman MD[3], Bocage C[1], Long M[2] |
[1]Carelon Research, Inc., Wilmington, DE, USA, [2]Duke University, Durham, NC, USA, [3]University of North Carolina Chapel Hill, Chapel Hill, NC, USA |
|
Poster Wednesday, August 28 |
Spotlight poster session C: adherence |
[CSPOT07] Factors associated with adherence to long-acting injectable antipsychotics among Medicare beneficiaries |
Chiang YY[1], Grabner M[2], Harris K[2], Teng CC[2], dosReis S[1] |
[1]University of Maryland School of Pharmacy, Baltimore, MD, USA, [2]Carelon Research, Wilmington, DE, USA |
|
Poster Wednesday, August 28 |
Spotlight poster session C: cancer |
[CSPOT39] Trajectories of antidepressant use after tamoxifen initiation among young and middle age women with breast cancer |
Onasanya O[1], Rosenblatt P[2], dosReis S[2], Onukwugha E[2], Zafari Z[2], Castillo WC[2] |
[1]Carelon Research, Wilmington, DE, USA, [2]University of Maryland School of Medicine, Baltimore, MD, USA |
